Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12327057 | 1.00 | CASP3 (0.46) | CASP3ALDH1A1POLBNPSR1GAA | |
| SCHEMBL29750066 | 1.00 | CASP3 (0.46) | CASP3ALDH1A1POLBNPSR1GAA | |
| SCHEMBL16414776 | 0.84 | LMNA (0.50) | CASP3ALDH1A1POLBNPSR1GAA | |
| SCHEMBL19285619 | 0.83 | CASP3 (0.46) | CASP3ALDH1A1POLBNPSR1GAA | |
| SCHEMBL19285617 | 0.83 | CASP3 (0.46) | CASP3ALDH1A1POLBNPSR1GAA | |
| SCHEMBL24387679 | 0.83 | CASP3 (0.46) | CASP3ALDH1A1POLBNPSR1GAA | |
| SCHEMBL29750000 | 0.83 | CASP3 (0.46) | CASP3ALDH1A1POLBNPSR1GAA | |
| SCHEMBL83756 | 0.83 | CASP3 (0.46) | CASP3ALDH1A1POLBNPSR1GAA | |
| SCHEMBL19285667 | 0.83 | CASP3 (0.46) | CASP3ALDH1A1POLBNPSR1GAA | |
| SCHEMBL12134371 | 0.82 | CASP3 (0.45) | CASP3ALDH1A1POLBNPSR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-8664256-B2 | Kinesin inhibitors as cancer therapeutics | NOVARTIS AG (CH) | 2014-03-04 | — | — | US | disclosed |
| US-8664256-B2 | Kinesin inhibitors as cancer therapeutics | NOVARTIS AG (CH) | 2014-03-04 | — | — | US | disclosed |
| EP-2229170-B1 | KINESIN INHIBITORS AS CANCER THERAPEUTICS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20130012560-A1 | KINESIN INHIBITORS AS CANCER THERAPEUTICS | ABRAMS TINYA (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012560-A1 | KINESIN INHIBITORS AS CANCER THERAPEUTICS | ABRAMS TINYA (US) | 2013-01-10 | — | — | US | disclosed |
| US-8252832-B2 | Kinesin inhibitors as cancer therapeutics | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-8252832-B2 | Kinesin inhibitors as cancer therapeutics | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-8129358-B2 | Substituted pyrazole and triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129358-B2 | Substituted pyrazole and triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-7626040-B2 | Substituted imidazole compounds as KSP inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090239922-A1 | Kinesin inhibitors as cancer therapeutics | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| US-20090239922-A1 | Kinesin inhibitors as cancer therapeutics | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| WO-2009077448-A1 | KINESIN INHIBITORS AS CANCER THERAPEUTICS | NOVARTIS AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG | 2008-08-21 | — | — | US | disclosed |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG | 2008-08-21 | — | — | US | disclosed |
| WO-2008063912-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007021794-A1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | KIF5B, KIF2C, KIF18B | CASP3 2758/4885ALDH1A1 1685/4885POLB 177/4885 |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | CASP3 1511/4885ALDH1A1 1512/4885POLB 2521/4885 |
| US-20090239922-A1 | Kinesin inhibitors as cancer therapeutics | KIF5B, KIF18B, KIF18A | CASP3 4234/4885ALDH1A1 1233/4885POLB 1694/4885 |
| US-20130012560-A1 | KINESIN INHIBITORS AS CANCER THERAPEUTICS | KIF5B, KIF18B, KIF18A | CASP3 4234/4885ALDH1A1 1233/4885POLB 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.